Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details the acquisition of Ordinary shares by specific individuals through the Company's ShareReward Plan on April 9, 2010. The shares were purchased at a price of £12.75 per Ordinary share. The transactions were executed under the Dividend Reinvestment element of the Plan, which was entered into on October 5, 2001.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of insider share purchases compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 9, 2010.
- Share Price: £12.75 per Ordinary share.
- Plan Type: ShareReward Plan (Dividend Reinvestment element).
- Participants: Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr S A Hussain, Mr D Learmouth, Dr D Pulman, Mr D S Redfern, and Ms C Thomas.
- Acquisition Volume: Most participants acquired 33 shares; Mr S A Hussain acquired 5 shares; Dr D Pulman acquired 11 shares.